TITLE

Former Chinese Orphans Find Each Other Again Because of Rare Disease They Share

AUTHOR(S)
Young, Susan
PUB. DATE
February 2015
SOURCE
People.com;2/27/2015, pN.PAG
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Mae Rainey and Mai Frandsen have thalassemia, which requires frequent transfusions or a bone marrow transplant
ACCESSION #
101214668

 

Related Articles

  • Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point? Hyde, Rebecca; Dobrovolny, Diana // American Health & Drug Benefits;Jan2010, Vol. 3 Issue 1, p15 

    The Orphan Drug Act of 1983 paved the way for the development of drugs that treat rare diseases, defined in the United States as those affecting fewer than 200,000 patients. Orphan drugs can cost hundreds of thousands of dollars annually, but insurers have traditionally covered these therapies...

  • Orphan Drug Development: A Brief Review. Singh, Manish Kumar; Sharma, Pramod Kumar; Sharma, Nitin // Journal of Pharmacy Research;Aug2011, Vol. 4 Issue 8, p2645 

    Orphan drugs the drugs which are introduced in market for the treatment of rare disease like congenital diseases, aplastic anemia etc. orphan drugs are This review mainly deals with the introduction of orphan drugs, orphan drug law, it also focuses on regulatory requirements related to the...

  • Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs. Denis, Alain; Mergaert, Lut; Fostier, Christel; Cleemput, Irina; Hulstaert, Frank; Simoens, Steven // PharmacoEconomics;2011, Vol. 29 Issue 10, p883 

    Background: Orphan medicinal products are designed to diagnose or treat rare diseases that are serious, life threatening or chronically debilitating and that affect 50 or fewer people in every 100 000 in the EU. In Belgium, the Drug Reimbursement Committee (DRC) evaluates reimbursement requests...

  • Drug development for exceptionally rare metabolic diseases: challenging but not impossible. Putzeist, Michelle; Mantel-Teeuwisse, Aukje K.; Gispen-de Wied, Christine C.; Hoes, Arno W; Leufkens, Hubert GM.; de Vrueh, Remco LA. // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, p1 

    Background We studied to what extent the level of scientific knowledge on exceptionally rare metabolic inherited diseases and their potential orphan medicinal products is associated with sponsors deciding to apply for an orphan designation at the US Food and Drug Administration (FDA) or the...

  • Orphan drugs policies: a suitable case for treatment. Drummond, Michael; Towse, Adrian // European Journal of Health Economics;May2014, Vol. 15 Issue 4, p335 

    Context: Current orphan drug policies are unsatisfactory when viewed from almost all perspectives. Patients find that, although therapies are available for many rare conditions, access to care is sometimes restricted. Pharmaceutical manufacturers have responded to the incentives for research...

  • Orphan Drug Law. Henkel, John // FDA Consumer;May/Jun99, Vol. 33 Issue 3, p29 

    Offers a look at the Orphan Drug Act of 1983 and how it has impacted the life of children and other people afflicted with rare types of disease. Definition of the Orphan Drug Act; Number of rare conditions that afflict people in the United States; Events that thrust the orphan issue into the...

  • Orphan Drugs. Harrington, Anthony // Contract Pharma;Nov/Dec2013, Vol. 15 Issue 9, p98 

    The author reports on increasing reimbursement of orphan drugs, developed to treat rare diseases.

  • Gender and Ocular Manifestations of Connective Tissue Diseases and Systemic Vasculitides. Choudhary, Maria M.; Hajj-Ali, Rula A.; Lowder, Careen Y. // Journal of Ophthalmology;2014, p1 

    Ocular manifestations are present in many connective tissue diseases which are characterized by an immune system that is directed against self. In this paper, we review the ocular findings in various connective tissue diseases and systemic vasculitides and highlight gender differences in each...

  • Orphan Products: Hope for People With Rare Diseases. Rados, Carol // FDA Consumer;Nov/Dec2003, Vol. 37 Issue 6, p10 

    Focuses on the efforts of the U.S. government, patient groups and the pharmaceutical industry to address people with orphan diseases. Background on the orphan disease; Prevalence of orphan diseases in the U.S.; Challenges associated with the diagnosis and management of orphan diseases;...

  • PTC124 Can Save the World One Orphan at a Time.  // Bioworld Week;2/11/2008, Vol. 16 Issue 6, p1 

    The article reports on the preclinical findings of PTC124 drug which received orphan drug designation for the treatment of cystic fibrosis. The disease is rare and only 10% of such cases are due to nonsense mutations. However, the drug could find a large market because it is not aimed at one...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics